Myo-Inositol: What It Does for Insulin Resistance and PCOS

A closer look at how this vitamin-like compound affects blood sugar, ovulation, and hormone balance.

Track the foods that fit your goals. Track it free with Ration →

By the Ration Editorial Team · Reviewed against primary research · Updated July 14, 2026

Myo-inositol is a naturally occurring sugar alcohol, sometimes called vitamin B8, though it is not officially classified as a vitamin.

The body makes it from glucose, and it is also found in certain foods.

It plays a structural role in cell membranes and acts as a second messenger in insulin signaling pathways.

Its close relative, D-chiro-inositol, works alongside it, and the two are often studied together^[2].

Myo-inositol helps cells respond to insulin by supporting the signaling cascade that moves glucose from the bloodstream into cells.

When this signaling is impaired, a state known as insulin resistance, cells need more insulin to do the same job.

This is central to conditions like polycystic ovary syndrome (PCOS), where insulin resistance often drives excess androgen production and disrupted ovulation^[4].

By improving insulin sensitivity, myo-inositol may indirectly support more regular menstrual cycles and lower testosterone levels in some women^[1].

The strongest and most consistent data point involves HOMA-IR, a calculated measure of insulin resistance based on fasting glucose and insulin.

• ↓HOMA-IRAHuman trials

  Research may lower HOMA-IR · strong agreement · 6 studies

  View 5 studies on PubMed

  • Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024)
  • Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS) (2017)
  • Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study (2022)
  • Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022)
  • Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes (2022)

A 2024 systematic review and meta-analysis, conducted to inform international PCOS guidelines, found that inositol supplementation improved insulin resistance markers and supported the case for its use in PCOS management^[1].

A randomized open-label trial comparing myo-inositol plus D-chiro-inositol to standard care found improvements in both menstrual cycle regularity and insulin resistance in young women with PCOS^[2].

A head-to-head trial against metformin, a common insulin-sensitizing medication, found myo-inositol produced comparable improvements in insulin sensitivity in women with PCOS^[5].

Broader reviews describe myo-inositol's relevance across insulin resistance, metabolic syndrome, PCOS, and even gestational diabetes, though the depth of evidence varies by condition^[3].

Some research has also explored inositol's role in modulating insulin resistance alongside abnormal cell growth pathways, an area that is still preliminary^[6].

Myo-inositol occurs naturally in a variety of whole foods.

• Citrus fruits, especially cantaloupe and oranges
• Whole grains like brown rice and oats
• Legumes such as chickpeas and lentils
• Nuts, including almonds and peanuts
• Organ meats like liver

Supplement forms are typically sold as pure myo-inositol powder or capsules, sometimes combined with D-chiro-inositol in ratios that mimic what is found naturally in the body.

Clinical trials in PCOS have generally used doses in the range of 2 to 4 grams of myo-inositol daily, often split into two doses.

Combination products pairing myo-inositol with D-chiro-inositol typically use a 40 to 1 ratio, reflecting the natural proportion found in human tissue^[2].

Trial durations commonly range from 3 to 6 months before insulin resistance or menstrual outcomes are reassessed.

Myo-inositol is generally described as well tolerated in the trials reviewed.

• Mild digestive symptoms like nausea or bloating are the most commonly reported side effects
• Side effects appear less frequent than with metformin in comparative trials^[5]
• Long-term safety data beyond several months of use is still limited

This is not medical advice, and anyone considering supplementation, especially during pregnancy or alongside diabetes medications, should discuss it with a healthcare provider first.

The evidence base centers almost entirely on women with PCOS or related insulin resistance.

• Women with PCOS looking to support insulin sensitivity and cycle regularity^[1][2]
• People with metabolic syndrome features, though evidence here is less robust^[3]
• Those exploring alternatives to metformin who want to discuss options with a doctor^[5]

People without insulin resistance or PCOS have little direct evidence to draw on for using myo-inositol.

Myo-inositol has some of the more consistent clinical evidence among PCOS-related supplements, particularly for lowering HOMA-IR and supporting insulin sensitivity^[1][3].

Its comparability to metformin in some trials makes it a topic worth discussing with a healthcare provider, especially for women managing PCOS-related insulin resistance^[5].